## **Corrections & amendments**

## Author Correction: Etrasimod for ulcerative colitis: evaluating phase III results

Correction to: Nature Reviews Gastroenterology & Hepatology https:// doi.org/10.1038/s41575-023-00793-0. Published online 23 May 2023.

https://doi.org/10.1038/s41575-023-00817-9

Published online: 3 July 2023

Check for updates

## Katsuyoshi Matsuoka 🛛 & Toshifumi Hibi 🔊

In the version of this article originally published online, there was an error in the seventh paragraph: in the text now reading "Additionally, the half-life of etrasimod is shorter than ozanimod (-30 hours versus up to 11 days)," the half-life of etrasimod was originally given as "11 hours". The error has been corrected in the HTML and PDF versions of the article.

© Springer Nature Limited 2023